These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 14678865

  • 21. Diabetes medications and body weight.
    Mitri J, Hamdy O.
    Expert Opin Drug Saf; 2009 Sep; 8(5):573-84. PubMed ID: 19538102
    [Abstract] [Full Text] [Related]

  • 22. Thiazolidinediones.
    Yki-Järvinen H.
    N Engl J Med; 2004 Sep 09; 351(11):1106-18. PubMed ID: 15356308
    [No Abstract] [Full Text] [Related]

  • 23. Durability of glycemic control: a feature of the thiazolidinediones.
    Serdy S, Abrahamson MJ.
    Diabetes Technol Ther; 2004 Apr 09; 6(2):179-89. PubMed ID: 15117584
    [Abstract] [Full Text] [Related]

  • 24. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.
    Soccio RE, Chen ER, Lazar MA.
    Cell Metab; 2014 Oct 07; 20(4):573-91. PubMed ID: 25242225
    [Abstract] [Full Text] [Related]

  • 25. Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes.
    Toprani A, Fonseca V.
    Diabetes Obes Metab; 2011 Mar 07; 13(3):276-80. PubMed ID: 21205120
    [Abstract] [Full Text] [Related]

  • 26. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
    Hanefeld M.
    Int J Clin Pract Suppl; 2007 Jun 07; 61(153):20-7. PubMed ID: 17594390
    [Abstract] [Full Text] [Related]

  • 27. Insulin resistance as the core defect in type 2 diabetes mellitus.
    Goldstein BJ.
    Am J Cardiol; 2002 Sep 05; 90(5A):3G-10G. PubMed ID: 12231073
    [Abstract] [Full Text] [Related]

  • 28. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.
    Clin Ther; 2011 Dec 05; 33(12):1904-13. PubMed ID: 22118894
    [Abstract] [Full Text] [Related]

  • 29. Management of type 2 diabetes mellitus. Role of thiazolidinediones.
    Noble J, Baerlocher MO, Silverberg J.
    Can Fam Physician; 2005 May 05; 51(5):683-7. PubMed ID: 15934272
    [Abstract] [Full Text] [Related]

  • 30. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance.
    de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF.
    Diabetes; 2001 Aug 05; 50(8):1863-71. PubMed ID: 11473050
    [Abstract] [Full Text] [Related]

  • 31. Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes.
    Watanabe Y, Nakayama K, Taniuchi N, Horai Y, Kuriyama C, Ueta K, Arakawa K, Senbonmatsu T, Shiotani M.
    PLoS One; 2015 Aug 05; 10(1):e0116851. PubMed ID: 25615826
    [Abstract] [Full Text] [Related]

  • 32. Treatment of insulin resistance in diabetes mellitus.
    Lebovitz HE, Banerji MA.
    Eur J Pharmacol; 2004 Apr 19; 490(1-3):135-46. PubMed ID: 15094080
    [Abstract] [Full Text] [Related]

  • 33. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE, Hanna A.
    Diabetes Obes Metab; 2008 Apr 19; 10(4):312-28. PubMed ID: 18333890
    [Abstract] [Full Text] [Related]

  • 34. Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones.
    Wyne KL, Drexler AJ, Miller JL, Bell DS, Braunstein S, Nuckolls JG.
    Postgrad Med; 2003 May 19; Spec No():63-72. PubMed ID: 12785133
    [Abstract] [Full Text] [Related]

  • 35. Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus.
    Kudzma DJ.
    Am J Manag Care; 2002 Oct 19; 8(16 Suppl):S472-82. PubMed ID: 12408410
    [Abstract] [Full Text] [Related]

  • 36. Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations.
    Sheu WHH, Chan SP, Matawaran BJ, Deerochanawong C, Mithal A, Chan J, Suastika K, Khoo CM, Nguyen HM, Linong J, Luk A, Yoon KH.
    Diabetes Metab J; 2020 Feb 19; 44(1):11-32. PubMed ID: 32097996
    [Abstract] [Full Text] [Related]

  • 37. Does Weight Gain Associated with Thiazolidinedione Use Negatively Affect Cardiometabolic Health?
    Ko KD, Kim KK, Lee KR.
    J Obes Metab Syndr; 2017 Jun 19; 26(2):102-106. PubMed ID: 31089503
    [Abstract] [Full Text] [Related]

  • 38. Recent findings concerning thiazolidinediones in the treatment of diabetes.
    Boden G, Zhang M.
    Expert Opin Investig Drugs; 2006 Mar 19; 15(3):243-50. PubMed ID: 16503761
    [Abstract] [Full Text] [Related]

  • 39. Beyond glycemic control: treating the entire type 2 diabetes disorder.
    Brunton S.
    Postgrad Med; 2009 Sep 19; 121(5):68-81. PubMed ID: 19820276
    [Abstract] [Full Text] [Related]

  • 40. [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].
    Dubois M, Vantyghem MC, Schoonjans K, Pattou F.
    Ann Endocrinol (Paris); 2002 Dec 19; 63(6 Pt 1):511-23. PubMed ID: 12527853
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.